Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Guide17 min read

Weight Loss Pills in 2026: Every Prescription Option, Compared

Disclosure: we may earn a commission when you click a provider link. It never affects our rankings, prices or verdicts, which come from verified sources.

The two FDA-approved GLP-1 pills, the older prescription pills, the compounded tablets and the over-the-counter products, clearly labelled: what each one does, what the evidence shows, what it costs and who must not take it.

Updated October 22, 2026

Medically reviewed on

How we review

The quick answerThe strongest weight loss pills are the two FDA-approved GLP-1 tablets: the Wegovy pill (oral semaglutide 25 mg, approved December 2025), which produced 13.6% mean weight loss in its trial, and Foundayo (orforglipron, approved April 1, 2026), which produced 11.2%. Below them sit the older prescription pills - Qsymia, Contrave, phentermine and orlistat - at roughly 3-10%, and below those the over-the-counter products with little evidence behind them. The GLP-1 pills cost $149-$349 a month self-pay as reported, $149 then $299 plus membership at Ro (verified), $25 with commercial coverage and $50 on Medicare's pilot. Compounded oral semaglutide sold by some telehealth programs is a different, non-FDA-approved product.Trial figures are the published treatment-policy results linked below. Ro’s price is its own published figure, verified August 2026; manufacturer prices are as reported by dated sources and not verified by us.

Key takeaways

  • Two GLP-1 pills are FDA-approved for chronic weight management: the Wegovy pill (13.6% mean weight loss at 64 weeks in OASIS 4) and Foundayo (11.2% at 72 weeks in ATTAIN-1). Rybelsus is oral semaglutide at diabetes doses and is not approved for weight loss.
  • The older FDA-approved pills still have a place: Qsymia (phentermine/topiramate) and Contrave (naltrexone/bupropion) for long-term use, phentermine for short-term use, and orlistat, which blocks part of dietary fat. Each has specific people who must not take it.
  • Price is about the route. Verified: the Wegovy pill at Ro is $149 the first month then $299 plus membership. Reported: Foundayo $149-$349 self-pay, $25 with commercial coverage for either pill, $50 on Medicare's GLP-1 Bridge through December 2027.
  • Compounded oral semaglutide or tirzepatide is not the Wegovy pill: it is a legal pharmacy-prepared product with no trials of its own and no FDA approval. Over-the-counter diet pills have been found by the FDA to contain hidden, banned drugs.

Do weight loss pills work? The short version

Some do, and the answer changed in the last year. For two decades "weight loss pill" meant either a modest prescription option or an over-the-counter product with a bold label and thin evidence. Two things are different now. First, two GLP-1 medications - the same class as Ozempic, Wegovy and Zepbound - are FDA-approved as daily tablets for chronic weight management: the Wegovy pill (oral semaglutide 25 mg), approved in December 2025, and Foundayo (orforglipron, Eli Lilly), approved on April 1, 2026. In their trials they produced 13.6% and 11.2% mean weight loss, and the Wegovy pill's result is described by its own trial authors as similar to the weekly semaglutide injection. Second, the older prescription pills have not gone away; they still suit people who cannot take a GLP-1, cannot afford one, or do not need that much.

The evidence sorts the options into four tiers, and this guide walks them in that order:

  • The FDA-approved GLP-1 pills - the Wegovy pill and Foundayo, plus Rybelsus, which is semaglutide at diabetes doses and is not approved for weight loss.
  • The older FDA-approved prescription pills - Qsymia, Contrave, phentermine and orlistat - at roughly 3-10% average weight loss, each with people who must not take it.
  • Compounded oral semaglutide and tirzepatide - sold by some telehealth programs, legal under conditions, not FDA-approved and without trials of their own.
  • Over-the-counter "diet pills" - the category the FDA keeps finding hidden, banned drugs in.

Prefer injections? Our guides to semaglutide and tirzepatide providers cover them, and GLP-1 pills vs injections compares the two formats line by line.

The FDA-approved GLP-1 pills: Wegovy pill, Foundayo and Rybelsus

These are the same class of medication as the injections, in tablet form. The trial figures are the published New England Journal of Medicine results counting everyone randomised; both manufacturers also quote higher on-treatment figures (16.6% for the Wegovy pill, 12.4% for Foundayo), which describe people who took the pill as directed to the end. Prices are Ro's verified published figures and manufacturer prices as reported by the sources linked in the cost section.

PillStatus and how it is takenTrial resultPublished price
Wegovy pill (oral semaglutide 25 mg), Novo NordiskApproved December 2025 for chronic weight management. Once daily on an empty stomach with a sip of water, then a 30-minute wait before foodOASIS 4 (64 weeks): 13.6% mean weight loss vs 2.2% on placebo; 30% lost 20% or moreRo: $149 first month, then $299, plus membership (verified). NovoCare self-pay reported at $149-$299 by dose; $25 with commercial coverage (reported)
Foundayo (orforglipron), Eli LillyApproved April 1, 2026. Small-molecule GLP-1: once daily, any time, no food or water restrictions; six tablet strengths from 0.8 mg to 17.2 mgATTAIN-1 (72 weeks): 11.1% mean weight loss at the 17.2 mg top strength vs 2.1% on placebo (FDA label, rev. 7/2026); 18% lost 20% or moreLillyDirect self-pay $149-$349 a month by dose; $25 a month with commercial coverage (Lilly, as reported)
Rybelsus (oral semaglutide 7-14 mg), Novo NordiskApproved for type 2 diabetes, not for weight management. Same empty-stomach rule as the Wegovy pillModest weight loss at diabetes doses, well below the 25 mg Wegovy pillPrescribed under its diabetes label; weight-loss use is off-label and not covered as such

The Wegovy pill

Semaglutide is a peptide, and peptides are poorly absorbed from the gut, which is why the tablet carries 25 mg against the injection's 2.4 mg a week and why it comes with a rule: take it on an empty stomach with a small sip of water, then wait about 30 minutes before eating, drinking or taking other medicines. Miss the timing and absorption drops. The dose is stepped up over the first months from a 1.5 mg starting tablet to the 25 mg maintenance dose that produced the trial result. It is approved for reducing excess body weight and maintaining the loss in adults with obesity, or overweight with a weight-related condition, and for lowering cardiovascular risk in that group. Wegovy pill price online walks every route to it.

Foundayo

Orforglipron is not a peptide but a small molecule, designed to be absorbed the way most ordinary tablets are. That is what lets it be taken at any time of day with or without food or water, stepped up across six tablet strengths from 0.8 mg to 17.2 mg. Its published result is smaller than the Wegovy pill's, with the caveat that the two were tested in separate trials of different lengths and nobody has run them head to head. For someone who takes morning medication, drinks coffee on waking or simply will not keep a timed routine, the absence of rules is its main argument. Foundayo vs the Wegovy pill compares them line by line.

Rybelsus

Rybelsus is the same semaglutide molecule at 7 mg and 14 mg, approved for type 2 diabetes. People lose some weight on it, but the doses are far below the 25 mg weight-management tablet, it carries the same empty-stomach rule, and insurance will not cover it for weight loss because that is not its label. If you are offered Rybelsus "for weight loss", you are being offered an off-label diabetes drug when an approved weight-loss version of the same molecule now exists.

Our top 2 picks

Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.

Our Top Pick
1
embody logo

Exceptional

9.8out of 10

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Free expedited deliveryNo hidden fees
  • Compounded semaglutide ($49/mo) and tirzepatide ($99/mo) as shown on the homepage, Nov 16, 2026; not FDA-approved
  • Online intake, then a prescriber review by OpenLoop Health, a network of US-licensed doctors
  • Free expedited delivery (embody's words); the Terms do not guarantee a delivery timeline
  • No insurance required, no clinic visits; cancel at least 72 hours before the next billing date

from $49/month

Doctor-prescribed compounded GLP-1 treatment, not FDA-approved: semaglutide shown at $49/month and tirzepatide at $99/month on embody's homepage (Nov 16, 2026), no insurance required.

Read full embody review
2
altRx logo

Excellent

9.4out of 10

Most Comprehensive GLP-1 Medication Access

Transparent pricingNo insurance required
  • Compounded GLP-1 from $89/mo, GLP-1 + GIP from $149/mo
  • Brand-name options too: Zepbound and Wegovy
  • Clinician-guided - physician, PA, or nurse practitioner
  • Free shipping (about 5-7 days)

from $89/month

Affordable GLP-1 program from $89/month - compounded semaglutide and tirzepatide plus brand-name options - with clinician-guided, self-pay care and no insurance required.

Read full altRx review

How the GLP-1 pills compare with the injections

The honest summary: injections still deliver the greatest average weight loss, the Wegovy pill now matches semaglutide injections in its own trial, and Foundayo removes the needle and the timing rules.

FactorGLP-1 pillsGLP-1 injections
Average weight loss in trials13.6% (Wegovy pill, OASIS 4) and 11.2% (Foundayo, ATTAIN-1) at their top doses14.9% (semaglutide, STEP 1) to 20.9% (tirzepatide 15 mg, SURMOUNT-1)
FormatDaily tablet, no needlesOnce-weekly injection from a pen or a compounded vial
Published priceFrom $149 a month at the starting dose; $299 (Wegovy pill) to $349 (Foundayo) at the top dose, as reported; $25 with commercial coverageBrand pens $1,149-$1,799 a month cash at providers we track; compounded from $41 (semaglutide) and $71 (tirzepatide)
RoutineWegovy pill and Rybelsus need empty-stomach timing; Foundayo does notOne dose a week, nothing in between
Best forNeedle-averse patients; those who want a daily routine or, with Foundayo, no rules at allThose prioritising the greatest average weight loss, or the lowest cash price via compounded

Side effects do not split by format: the pills and the injections share the same gastrointestinal profile, mostly early and around dose increases, and the same class warnings. The full comparison, including year-one costs and the routine in detail, is in GLP-1 pills vs injections.

The older FDA-approved prescription pills, one by one

Before the GLP-1s, these were the prescription weight loss pills, and they are still prescribed every day. They work in different ways - appetite suppression, craving reduction, blocking fat absorption - and produce less weight loss on average than the GLP-1 pills, generally at lower prices because most are generic. The NIDDK's overview of prescription medications for overweight and obesity lists them with their approvals; the typical results below are the ranges this guide has carried, and individual results vary widely.

PillHow it works and who must not take itTypical results
Qsymia (phentermine/topiramate ER)Appetite suppression plus reduced cravings; a once-daily capsule stepped up over the first weeks, with a weight check at 12 weeks. Not for use in pregnancy (topiramate causes birth defects); contraindicated in glaucoma and hyperthyroidismAmong the most effective non-GLP-1 pills, roughly 8-10% average weight loss
Contrave (naltrexone/bupropion)Targets appetite and reward-related eating; a daily tablet. Boxed warning for suicidal thoughts and behaviour; not with opioids, seizure disorders, uncontrolled high blood pressure or MAO inhibitorsRoughly 5-9% average weight loss
Phentermine (Adipex-P and generics)Short-term appetite suppressant; a controlled stimulant with cardiovascular cautions, approved for a few weeks of useRoughly 3-5% over short-term use
Orlistat (Xenical by prescription, Alli over the counter)Blocks absorption of part of the fat you eat; taken with meals. Gastrointestinal side effects are common and track the fat in the mealRoughly 3-5%
MetforminA diabetes drug used off-label for weight; improves insulin sensitivity. Not FDA-approved for weight lossModest, around 2-3%; often used as a lower-cost option

Qsymia

Qsymia combines phentermine with an extended-release form of topiramate, a seizure and migraine medicine that also reduces appetite. It is prescribed for adults, and children aged 12 and over, with obesity or overweight and a weight-related condition, alongside a reduced-calorie diet and exercise; the MedlinePlus monograph describes the low starting dose, the step-up after 14 days and the 12-week check at which a clinician decides whether to continue, increase or stop. The hard rules come from topiramate: it can cause birth defects, so a negative pregnancy test before starting and reliable contraception during treatment are required, and it is contraindicated in glaucoma and overactive thyroid. On the published figures it is the strongest of the older pills.

Contrave

Contrave combines naltrexone, an opioid blocker, with bupropion, an antidepressant also sold to help people stop smoking. The MedlinePlus monograph opens on its boxed warning: bupropion has been linked to suicidal thoughts in a small number of young people in studies, and anyone on it should be watched for mood changes. It must not be taken with opioids (naltrexone blocks them and can trigger withdrawal), by people with seizure disorders or uncontrolled high blood pressure, or within 14 days of an MAO inhibitor. For the right patient, often someone whose eating is driven by cravings rather than hunger, it is a reasonable, generic-era option.

Phentermine

Phentermine on its own is the oldest drug on this list and still the most prescribed. It is a stimulant-type appetite suppressant and a controlled substance, approved for short-term use measured in weeks, with cautions around heart disease, high blood pressure, overactive thyroid, glaucoma and MAO inhibitors. It is inexpensive as a generic and it works while you take it; the weight tends to return after the course ends, which is why clinicians increasingly reserve it for a short start rather than a plan.

Orlistat

Orlistat works in the gut rather than the brain: it blocks the enzyme that digests fat, so part of the fat in a meal passes through unabsorbed. The 120 mg prescription strength is Xenical; the 60 mg strength, Alli, is the only over-the-counter weight-loss medicine with an FDA approval behind it. Its side effects are the direct consequence of its mechanism - oily stools, urgency, gas - and they scale with how much fat is in the meal, which in practice teaches a low-fat diet. It also reduces absorption of fat-soluble vitamins, so a daily multivitamin taken apart from the dose is standard advice.

Metformin

Metformin is a type 2 diabetes medicine that some clinicians prescribe off-label for weight, particularly for people with insulin resistance or prediabetes. The effect is modest, it is not FDA-approved for weight loss, and it is on this list because it is cheap, familiar and often the first thing a primary-care doctor reaches for. It is not a substitute for any of the drugs above when the goal is substantial weight loss.

What weight loss pills cost, by route

Two different price worlds sit on this page. The GLP-1 pills are new brand-name products priced like brand-name products, with savings cards and a Medicare pilot that change the number entirely. The older pills are mostly generic and generally inexpensive at a retail pharmacy; we do not quote figures for them because they vary by pharmacy and plan, and your pharmacist can give you the cash price in a minute. The GLP-1 figures below are Ro's own published prices, verified by us in August 2026, and manufacturer prices as reported by the dated sources linked, which we have not verified.

RouteWegovy pillFoundayo
Telehealth (verified)Ro: $149 first month, then $299, plus membership ($39 first month, then $74-$149)Available through LillyDirect and telehealth providers per Lilly; none of the providers we track has published a price we could verify
Manufacturer direct, self-pay (reported)$149-$299 a month by dose through NovoCare Pharmacy, per third-party trackers; not verified by us$149-$349 a month by dose through LillyDirect, as reported by Scientific American from Lilly material
Commercial insurance that covers the drug (reported)as low as $25 with Novo Nordisk's savings offer, capped at $100 of savings per 30-day supply$25 with Lilly's savings card, per its April 9, 2026 release
Medicare GLP-1 Bridge$50 flat copay$50 flat copay

The Medicare GLP-1 Bridge is a CMS pilot running July 1, 2026 through December 31, 2027, covering the Wegovy pill and injection, the Zepbound KwikPen and Foundayo at $50 a month regardless of dose, with eligibility and approval through your Part D plan; neither savings card works on Medicare or Medicaid. For context, compounded semaglutide injections run $41-$199 a month and compounded tirzepatide $71-$299 at the providers we track, verified on each provider's site on November 3, 2026, which is why a needle-averse reader paying cash should read what $100-$200 a month gets you before deciding the pill is worth the premium. Our insurance guide explains how to check your formulary first, and GLP-1s after 65 covers the Medicare questions.

Compounded oral semaglutide and tirzepatide: not FDA-approved

Several telehealth providers offer compounded oral forms of semaglutide or tirzepatide - tablets, sublingual drops or dissolving films - alongside their injections, and some market them simply as "the pill". They are prepared by licensed 503A compounding pharmacies for an individual prescription, under the framework described on the FDA's human drug compounding page. That is a legal, regulated channel, but it is a different thing from the pills above: compounded products are not FDA-approved, they have no trials of their own, and an oral compounded peptide is absorbed differently from the approved 25 mg tablet, which went through specific formulation work to survive the stomach. The FDA's statement on unapproved GLP-1 drugs sets out its concerns: no pre-market review for safety, effectiveness or quality; adverse-event reports including dosing errors; and products found to contain salt forms of semaglutide that are not the approved active ingredient.

Their advantage is price and a familiar provider relationship, and the honest framing is this: a compounded oral product is a bet that the pharmacy's formulation delivers enough of the drug, with no published evidence that it does. If you want a pill with evidence behind it, the two approved pills are the pills. If price decides and you can accept an injection, the compounded injections below are the same molecules with far more real-world use. The trade-offs are set out in compounded vs brand-name and the 503A vs 503B explainer. A licensed clinician reviews your health profile and decides whether an oral or injectable option is the right fit; no in-person visit is required.

Providers with compounded oral options

embody logo
  • Semaglutide $49/mo, tirzepatide $99/mo - flat pricing (pre-Black Friday sale)
  • Free expedited delivery, no insurance required
  • Licensed doctors, LegitScript-certified, 503A pharmacies
TrimRx logo
  • No insurance required
  • Flexible treatment plans available
  • Ongoing clinical guidance included
Medvi logo
  • 100% online medical visit
  • Free shipping
  • No insurance required
SHED logo
  • Lose up to 20% of body weight
  • Science-backed GLP-1 medications
  • Multiple treatment options available

Over-the-counter diet pills: what the FDA keeps finding

Most non-prescription weight loss products - "fat burners", appetite "blockers", herbal blends, detox teas - have little or no rigorous evidence behind their claims, and they are not regulated the way prescription medicines are. The risk is not only that they do nothing. The FDA has repeatedly tested weight-loss supplements sold online and in stores and found hidden prescription drugs in them, most often sibutramine, a weight-loss drug withdrawn from the US market in 2010 because it raised blood pressure and heart rate and increased cardiovascular risk. The agency's February 2023 notice on Alfia Weight Loss Capsules is one of a long series, and the FDA has said it cannot test every product on the market, so absence from its list is not reassurance.

The one over-the-counter product with an FDA approval behind it is orlistat 60 mg (Alli), described above. Everything else sold without a prescription for weight loss should be treated as unproven at best. If you are serious about results, a licensed clinician and an FDA-approved medication are the evidence-based path, and every option on this page except Alli requires exactly that.

If you have already taken an over-the-counter weight-loss product and feel unwell - racing heart, chest pain, severe headache or a spike in blood pressure - seek care and tell them what you took. The FDA accepts reports of suspect products through its MedWatch programme.

Who should not take weight loss pills

Every pill here has a group of people who must not take it, and the intake form at a legitimate provider exists to find them. The non-negotiables, from the labels:

  • Pregnancy and breastfeeding. None of these medicines is used in pregnancy. Qsymia is the strictest because topiramate causes birth defects: a pregnancy test before starting and reliable contraception throughout.
  • GLP-1 pills (Wegovy pill, Foundayo, Rybelsus). Contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; warnings about pancreatitis and gallbladder disease; the Wegovy pill's absorption rule means other morning medicines need rescheduling.
  • Qsymia. Glaucoma, overactive thyroid, and within 14 days of an MAO inhibitor; topiramate can also affect mood, memory and kidney-stone risk.
  • Contrave. Any opioid use, seizure disorders, uncontrolled high blood pressure, an eating disorder history, abrupt withdrawal from alcohol or sedatives, and MAO inhibitors; the boxed warning on suicidal thoughts applies to everyone starting it.
  • Phentermine. Heart disease, uncontrolled high blood pressure, overactive thyroid, glaucoma, a history of drug misuse, and MAO inhibitors.
  • Orlistat. Chronic malabsorption or gallbladder problems; it also changes the absorption of some other medicines, including thyroid hormone and some anticoagulants, which need spacing.

Two general points. All of these are prescription medicines in a treatment plan, not a purchase, and the clinician who prescribes one is also the person who manages side effects and decides when to stop. And weight returns when most of them stop; the GLP-1 extension studies showed about two-thirds of lost weight regained within a year of stopping semaglutide, and the older pills behave the same way in practice, so the realistic question is which option you can sustain.

Which weight loss pill should you choose?

There is no universal answer, but most readers fit one of these.

You want the strongest pill and your insurance covers a GLP-1. The Wegovy pill or Foundayo, whichever your plan covers, at a reported $25 a month with the savings card. Between the two, the Wegovy pill has the larger trial result and Foundayo has no timing rules.

You are on Medicare. Ask your Part D plan about the GLP-1 Bridge: both pills at a flat $50, no dose increase. Choose on routine and results, not price.

You want a GLP-1 pill and are paying cash. The Wegovy pill through Ro is the verified telehealth route today, at $149 then $299 plus membership; Foundayo's reference is LillyDirect's reported $149-$349. Budget for the maintenance-dose price, not the first month, and do not accept a compounded "pill" as a substitute.

You cannot take a GLP-1, or do not need that much. Qsymia is the strongest of the older pills, Contrave suits craving-driven eating, and both are long-term options with specific exclusions; a clinician who knows your history chooses between them.

You want the lowest cost with evidence behind it. Generic phentermine for a short start, or orlistat, both inexpensive at a pharmacy; or, if you can accept a weekly injection, compounded semaglutide from $41 a month, which produces far more weight loss than any older pill. Our provider comparison lists every verified compounded price.

You were about to buy an over-the-counter product. Read the FDA section above first. Alli is the one with an approval; the rest are a gamble on contents as much as on results.

Whatever you choose, the prescriber decides on your history, not on a table, and can decline to prescribe any of them.

How to get weight loss pills online

The process is the same for every prescription option: an online intake covering your weight, health history, medications and goals; a review by a licensed clinician; a prescription if appropriate, filled either by the provider's partner pharmacy and shipped to you or sent to a pharmacy of your choice where insurance applies; and follow-up as the dose steps up or at the 12-week check the older pills' labels call for. For the FDA-approved Wegovy pill, Ro is the provider we have verified. For compounded oral or injectable semaglutide and tirzepatide, the providers below and on our comparison all run a clinician review before prescribing. The complete guide to GLP-1 weight loss online walks every step, including what to check about the pharmacy and the refund terms if you are not approved.

This guide is general information, not medical advice. Prescription weight loss medications require evaluation and supervision by a licensed healthcare provider, who decides whether any of them is appropriate for you.

Weight loss pills: FAQ

Do weight loss pills actually work?

Prescription weight loss pills can work, and the gap to injections has narrowed. The two FDA-approved GLP-1 pills produced 13.6% (Wegovy pill, OASIS 4) and 11.2% (Foundayo, ATTAIN-1) mean weight loss in their trials; the older FDA-approved pills such as Qsymia and Contrave produce roughly 5-10%. Over-the-counter 'fat burner' or 'natural' pills are largely unproven and are not a substitute for prescription treatment.

Is there a weight loss pill as effective as Ozempic or Wegovy?

Yes, for semaglutide. The Wegovy pill (oral semaglutide 25 mg), FDA-approved in December 2025, produced 13.6% mean weight loss at 64 weeks in OASIS 4, an effect the trial authors describe as similar to the weekly Wegovy injection in its own trial. Foundayo (orforglipron), approved April 1, 2026, reached 11.2% at its top dose. Injectable tirzepatide (Zepbound) still leads on average results, at 20.9% at the top dose in SURMOUNT-1.

What is the strongest prescription weight loss pill?

On published trial results, the Wegovy pill (oral semaglutide 25 mg) at 13.6% mean weight loss, followed by Foundayo at 11.2%; separate trials, not head to head. Among the non-GLP-1 pills, Qsymia (phentermine/topiramate) tends to produce the most weight loss, roughly 8-10% on average.

How much do the FDA-approved GLP-1 pills cost?

At the one telehealth route we have verified, Ro sells the Wegovy pill at $149 for the first month, then $299 a month, plus a $39-then-$74-149 membership. Novo Nordisk's direct-pay tiers are reported at $149-$299 by dose, and Foundayo lists $149-$349 a month self-pay through LillyDirect. Both manufacturers offer a $25-a-month savings card with commercial coverage, and both pills are in Medicare's $50 GLP-1 Bridge pilot through December 2027.

Can you get weight loss pills online?

Yes. Licensed telehealth providers can evaluate you online and, when appropriate, prescribe oral weight loss medication. Ro sells the FDA-approved Wegovy pill; several providers we review offer compounded oral semaglutide or tirzepatide, which are not FDA-approved products. A clinician determines whether an oral or injectable option fits your health profile.

Are compounded weight loss pills the same as the Wegovy pill or Foundayo?

No. The Wegovy pill and Foundayo are FDA-approved finished drugs with their own trials. Compounded oral semaglutide or tirzepatide is prepared by a licensed 503A pharmacy for an individual prescription; it is a legal, regulated channel, but the products are not FDA-approved, have no trials of their own, and absorb differently from the approved tablets. They are cheaper for that reason.

Who should not take weight loss pills?

It depends on the pill. The GLP-1 pills are contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Qsymia must not be used in pregnancy, glaucoma or hyperthyroidism. Contrave carries a boxed warning for suicidal thoughts and must not be combined with opioids, seizure disorders, uncontrolled high blood pressure or MAO inhibitors. Phentermine is a controlled stimulant with cardiovascular cautions. None of them is appropriate in pregnancy, and a licensed clinician screens for all of this before prescribing.

Are weight loss pills or injections better?

It depends on your priorities. Injections still produce the greatest average weight loss (tirzepatide 20.9% at the top dose), but the Wegovy pill now matches semaglutide injections in its own trial, and Foundayo removes the needle and the timing rules entirely. If maximum results matter most, injections lead today; if avoiding needles matters more, a GLP-1 pill is a strong fit. A clinician makes the call on your history.

Are over-the-counter diet pills safe?

Treat them with suspicion. Most have little evidence behind their claims, and the FDA has repeatedly found weight-loss supplements sold online that secretly contain sibutramine, a prescription drug withdrawn from the US market in 2010 for cardiovascular risk. Orlistat 60 mg (Alli) is the one over-the-counter weight-loss medicine with an FDA approval behind it.

Compare providers

Whether you lean toward a pill or an injection, the licensed telehealth providers we track are compared on verified pricing, medical support and value.

More GLP-1 guides

The rest of our weight-loss medication guides, kept to the same verified-price standard.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)

Sources: FDA approvals - the Wegovy pill (oral semaglutide 25 mg), approval announced December 22, 2025 (Healio); Foundayo (orforglipron), approved April 1, 2026 (FDA). Trial data: OASIS 4 and ATTAIN-1 as published in the New England Journal of Medicine, September 2025, summarised by the American College of Cardiology; STEP 1 and SURMOUNT-1 for the injections. The older pills are described from their labels as summarised on MedlinePlus (phentermine/topiramate, naltrexone/bupropion) and the NIDDK’s overview of prescription medications for overweight and obesity; their typical results are approximate ranges from their registration trials. Prices: Ro’s published pricing, verified August 2026; compounded prices verified November 3, 2026; Foundayo and NovoCare prices and savings cards as reported by Scientific American, Lilly’s April 9, 2026 release and third-party trackers, not verified by us. Weight-loss figures are trial averages; individual results vary. Trademarks belong to their manufacturers.

treatmentshub.com is not a medical provider and does not prescribe medications. This page is for educational and comparison purposes only and is not medical advice. Prescription weight loss medications require evaluation and supervision by a licensed healthcare provider. Always consult a qualified physician before starting any treatment.